Chapter title |
Brain-Derived Neurotrophic Factor as a Treatment Option for Retinal Degeneration
|
---|---|
Chapter number | 57 |
Book title |
Retinal Degenerative Diseases
|
Published in |
Advances in experimental medicine and biology, January 2018
|
DOI | 10.1007/978-3-319-75402-4_57 |
Pubmed ID | |
Book ISBNs |
978-3-31-975401-7, 978-3-31-975402-4
|
Authors |
Conor Daly, Rebecca Ward, Alison L. Reynolds, Orla Galvin, Ross F. Collery, Breandán N. Kennedy, Daly, Conor, Ward, Rebecca, Reynolds, Alison L., Galvin, Orla, Collery, Ross F., Kennedy, Breandán N. |
Abstract |
This review discusses the therapeutic potential of brain-derived neurotrophic factor (BDNF) for retinal degeneration. BDNF, nerve growth factor (NGF), neurotrophin 3 (NT-3) and NT-4/NT-5 belong to the neurotrophin family. These neuronal modulators activate a common receptor and a specific tropomyosin-related kinase (Trk) receptor. BDNF was identified as a photoreceptor protectant in models of retinal degeneration as early as 1992. However, development of effective therapeutics that exploit this pathway has been difficult due to challenges in sustaining therapeutic levels in the retina. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Ireland | 3 | 60% |
Unknown | 2 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Science communicators (journalists, bloggers, editors) | 1 | 20% |
Scientists | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 13 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 31% |
Student > Bachelor | 3 | 23% |
Other | 2 | 15% |
Researcher | 1 | 8% |
Unspecified | 1 | 8% |
Other | 0 | 0% |
Unknown | 2 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 23% |
Biochemistry, Genetics and Molecular Biology | 3 | 23% |
Neuroscience | 3 | 23% |
Unspecified | 1 | 8% |
Agricultural and Biological Sciences | 1 | 8% |
Other | 0 | 0% |
Unknown | 2 | 15% |